Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older

Next Previous
X
Search
Trial Profile

A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GRAd COV2 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms COVITAR
  • Sponsors ReiThera

    • Most Recent Events

    • 28 Mar 2023 Status changed from active, no longer recruiting to completed.
    • 16 Jun 2022 This trial has been completed in Italy according to European Clinical Trials Database record.
    • 12 Jul 2021 According to a ReiThera media release, Independent Data Safety Monitoring Board (independent Committee for the evaluation of safety) and the Steering Committee (Scientific Committee for the evaluation of efficacy) recommended the continuation of the clinical development of the GRAd-COV2 vaccine after reviewing the data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top